TRANSMITTAL FORM  (to be used for all correspondence after initial to			it and Trade	03
Total Number of Pages in This Submission	22	Attorney Docket Number	5853-238	8
	ENCL	OSURES (Check all tha	t apply)	
	Feman	<del></del>		After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):
TO THE RESIDENCE OF THE PARTY O	TURE O	F APPLICANT, ATTORN	EY, OR	AGENT
Firm AKERMAN SENTERFITT Gregory & Nelson, Regist Individual Signature  Date	ration No.	15/ 1- 1-D4		

Typed or printed Gregory A. Nelson Signature Date This collection of information is required by 37 CFB .5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U S C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the

Commissioner for Patents, Washington, DC 20231.

amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:



### **PATENT**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of DENSLOW et al.

Application No. 10/663,561

Examiner:

Filed: September 15, 2003

Group Art Unit: 1645

For:

DETECTING HORMONALLY ACTIVE COMPOUNDS

## **INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR §1.97(b)**

#### **CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA

2713- 430 011

Reg. No. 30,577

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO/SB/08A are hereby brought to the attention of the Examiner for independent evaluation. The references were cited in the specification of the present application.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Applicant respectfully requests that the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of form PTO/SB/08A be returned in accordance with MPEP §609.

# Certification

This Statement is being filed within three months of the filing of this application and/or prior to the issuance of the first Office Action for the present application, and this paper is thus submitted in accordance with 37 CFR §1.97(b). In view of this certification, a fee is not required for consideration of these documents. Nevertheless, should a fee be deemed to be due by the Commissioner, such fee should be charged to Deposit Account No. 50-0951.

Dated: 8 - 10 - 04

Docket No. 5853-238

Respectfully\submitted,

Gregory A Noison, Reg. No. 30,577

AKERMAN SENTERFITT

Post Office Box 3188

West Palm Beach, FL 33402-3188

Telephone: (561) 653-5000

AUG 1 3 2004 UNIVERSE Paper

PTO/SB/08B (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/663,561	
INFORMATION DISCLOSURE	Filing Date	09/15/2003	
STATEMENT BY APPLICANT	First Named Inventor	DENSLOW	
(Use as many sheets as necessary)	Art Unit	1645	
(030 do many should de necessary)	Examiner Name		
Sheet 1 of 1	Attorney Docket Number	5853-238	

	100	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Zacharewski, T. In Vitro Bioassays for Assessing Estrogenic Substances. Environmental Science and Technology. Vol. 31, No. 3. 1997; pages 613-623	
		Baker, V.A. Endocrine Disrupters-Testing Strategies to Assess Human Hazard. Toxicology in Vitro. Vol. 15. 2001; pages 413-419	
·			

Examiner		Date	
Signature	` .	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.